Donald Fredrickson: Spending Hughs' Legacy

In 1975, the Howard Hughes Medical Institute (HHMI) was remarkable more for its namesake, the legendary, ultra-reclusive billionaire, than for its $3 million research program. But Hughes' death in 1976, and the 1985 sale of the Hughes Aircraft Co. for $5 billion, have made the Institute remark-able to the tune of $200 million in biomedical grants last year alone. That figure is expected to climb to $300 million by 1990, making the Institute the largest private medical research organization in th

| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

We're not a private foundation and are not subject to private foundation rules. We don't want to be a private foundation, but we need clarification of the definition of an MRO. What does it allow us to do and not to do? We also want to know if there are any outstanding penalties or tax issues unresolved.

The Institute has been growing very fast. But it soon is going to come into equilibrium, because we now know what our endowment is. We intend to spend at least 3½ percent of that, and probably more, over the next few years. So our spending will increase a little bit relative to NIH, but not a great deal more. We still have to grow though; we're not fully mature in our new incarnation.

It was a direct ambition of ours not to get too concentrated. We're interested really in supporting excellent people, but ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies